Adding a Second Drug for Febrile Children Treated With Acetaminophen

Fever Clinical Trial

Official title:

Adding a Second Drug for Febrile Children Treated With Acetaminophen

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00389272
• Other study ID #: 53/05
• Status: Recruiting
• Phase: N/A
• First received: October 17, 2006
• Last updated: October 30, 2007
• Start date: September 2005
• Est. completion date: December 2008

Study information

• Verified date: October 2006
• Source: Assaf-Harofeh Medical Center
• Contact: Eran Kozer, MD
• Phone: 972 8 9779916
• Email: erank[@]asaf.health.gov.il
• Is FDA regulated: No
• Health authority: Israel: Israeli Health Ministry Pharmaceutical Administration
• Study type: Interventional

Clinical Trial Summary

Fever is one of the most common symptoms in pediatrics and one of the most common reasons for visits in pediatricians' office and pediatric emergency departments. Many parents consider fever to be the most terrifying symptom.

Acetaminophen and ibuprofen are both effective and safe treatments for febrile children. In order to achieve better temperature control and to avoid toxicity it has been suggested to treat febrile children with alternating doses of acetaminophen and ibuprofen. Surveys in the USA and Spain found that this practice is very common. However, The safety and efficacy of such practice was never described.

Hypothesis:

Children who are still febrile after being treated with acetaminophen or ibuprofen will have greater temperature decrement if treated with another drug (acetaminophen for those treated with ibuprofen and ibuprofen for those treated with acetaminophen) than if treated with placebo.

Description:

Methods:

Design: randomized double blind placebo controlled study. Setting: The ED and pediatric ward of a large University affiliated Hospital

Participants:

Inclusion criteria:

• Age: 6 mo- 4 years

• Rectal temperature > 38.5

• Received 10-15 mg/kg of acetaminophen or 5-10 mg/kg of ibuprofen 1.5 - 3.5 hours before admission to the ED.

Exclusion criteria:

• Received more than 75 mg acetaminophen in the last 24 hours

• Unable to take oral medications

• Hypersensitivity to acetaminophen or ibuprofen

• Varicella

• Renal failure

• Liver disease

• Rectal temperature can't be measured (due to anatomical or medical problem)

• Received both Ibuprofen and acetaminophen in the last 6 hours

• Informed consent could not be granted

Intervention:

Patients will be recruited in the ED and pediatric ward at Assaf Harofeh Medical Center. Legal guardians of eligible patients will be approached for consent. After obtaining informed consent a detailed history regarding the way fever was managed during the current illness will be collected (appendix 1). Patients will be randomized in a ratio of 2:1 (by a computer generated list of random numbers) into one of two groups. Group A will be treated with oral suspension of ibuprofen 10mg/kg (if the patient received acetaminophen at home) or oral suspension of acetaminophen 15 mg/kg (if treated previously with ibuprofen). The second group will be treated with the same amount of oral placebo suspension. The parents and the physician will be blinded to the treatment given. Body departure will be recoded at base line and at 15, 30, 60, 90, 120, 180 minutes after the drug administration. Blood sample for serum concentrations of acetaminophen or/and ibuprofen will be taken at the time of routine blood sampling according to the attending physician decision. Serum concentrations will not be measured if the attending physician decides that blood tests are not indicated.

Primary outcome:

· Maximal change in temperature during the 3-hour period after enrollment.

Secondary endpoints:

• Proportion of patients with a drop of at least 1°C and 2°C in mean temperature at the end of the study (3 hours).

• Decrement in fever at each time point, and the area under the temperature (versus time) curve for each group, calculated using the trapezoidal method. Continuous outcomes

• Proportion of patients with temperature < 38 at the end of the study (3 hours).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 6 Months to 4 Years

Eligibility

Inclusion Criteria:

• Age: 6 mo- 4 years

• Rectal temperature > 38.5

• Received 10-15 mg/kg of acetaminophen or 5-10 mg/kg of ibuprofen 1.5 - 3.5 hours before admission to the

Exclusion Criteria:

• Received more than 75 mg acetaminophen in the last 24 hours

• Unable to take oral medications

• Hypersensitivity to acetaminophen or ibuprofen

• Varicella

• Renal failure

• Liver disease

• Rectal temperature can't be measured (due to anatomical or medical problem)

• Received both Ibuprofen and acetaminophen in the last 6 hours

• Informed consent could not be granted

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fever

Intervention

Drug:
• Ibuprofen, acetaminophen

Locations

Country	Name	City	State
Israel	Pediatric Emergency Medicine Service, Assaf Harofeh Medical Center	Zerifin

Sponsors (1)

Lead Sponsor	Collaborator
Assaf-Harofeh Medical Center

Country where clinical trial is conducted

Israel,